Symposium 2022: Abstract Deadlines, Award Opportunities, and Sponsorship Prospectus
The Foundation will host the 8th International Symposium on Focused Ultrasound this October in Bethesda, Maryland.
Join Us– In-person and virtual registration is now open for the event.
Submit an Abstract– The final deadline to submit abstracts is Wednesday, June 1.
Award Opportunities– Apply for a Young Investigator Award by June 1 or nominate a colleague for the Ferenc Jolesz Memorial Award by June 6.
Support the Symposium– We invite organizations in the therapeutic ultrasound industry or related fields to view the Sponsor and Exhibitor Prospectus for advertising opportunities.
This month, the Foundation’s Brain Program Technical Director for the past 12 years, John Snell, PhD, began a new role as Manager of Advanced Simulation and Applications at Histosonics.
We celebrate John for his important work at the Foundation and contributions to advancing the field.
Previously, essential tremor patients in Germany who had focused ultrasound were only eligible for reimbursement if they were unsuitable for an alternate therapy – deep brain stimulation.
A recent ruling, thanks to a collaborative effort by physicians, has removed that barrier.
Researchers conducted a comprehensive literature review of studies using focused ultrasound to modulate anti-tumor immunity in the central nervous system.
Four bioeffects induce immune effects, improve immunotherapy trafficking, or turn "cold" tumors "hot."
When combined with immunotherapy, focused ultrasound can promote robust responses in brain tumors.
The annual meeting of the STM was held virtually May 1–4.
A special focused ultrasound symposium included research on immunotherapy, imaging, drug delivery, hyperthermia, pancreatic therapy, prostate cancer, and canine tumors.
The Foundation invites organizations in the therapeutic ultrasound industry or related fields to support the Symposium.
The Prospectus outlines a variety of sponsor and exhibitor packages, as well as many advertising opportunities to increase your company’s visibility at the meeting.
Histosonics will use GE Healthcare's LOGIQ E10 Series ultrasound imaging platform to improve visualization of its EdisonTM novel sonic beam therapy.
GE’s technology will offer continuous visualization for the histotripsy therapy procedure, including planning, monitoring, and immediate post-treatment verification.
Histosonics’ EdisonTM is now being used in clinical trials in the US and Europe to treat liver tumors.
